EGFR and non-small cell lung carcinoma: Additionally, the phase 3 Orient‐31 trial reported that sintilimab plus the bevacizumab biosimilar IBI305 and chemotherapy led to significant improvements in PFS over chemotherapy alone in patients with advanced EGFR‐mutated NSCLC after TKI failure (6.9 vs 4.3 months; p < 0.001).37